Top doctors raised concerns about domestically made drugs, saying Beijing’s effort to lower costs is sacrificing quality.

Zai Lab (ZLAB) announced that China’s National Medical Products Administration, NMPA, has accepted the New Drug Application, NDA, for KarXT for ...

Chinese regulators have accepted Zai Lab's (NASDAQ:ZLAB) market application for the drug KarXT, also known as xanomeline and ...

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS ® (savolitinib) has been granted approval by the China National Medical ...

Some of China’s senior doctors are raising concern over the quality of domestic generic medicines that have largely replaced western brand-name drugs at hospitals, amid a rare public backlash against ...

China is deepening its regulatory reforms of drugs and devices to foster a globally competitive innovation ecosystem to ...

Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...

China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why ...

A recent decision by a Chinese court to amend its judgment in a drug case involving a former associate chemistry professor — dubbed as the "Chinese version of Breaking Bad" — underscores the nation's ...